



# Proprietary Polymeric Prodrugs

Precise & Controlled Drug  
Delivery to the Eye

November 2025



# PolyActiva – Mission & Overview

## Delivering the Future of Ophthalmic Medicine



- Ophthalmology focussed biotechnology company
- Private, venture capital backed, raised ~ \$A90m
- Two clinical stage programs
  - Phase 2b clinical trial in glaucoma (6mths treatment)
  - Phase 1b clinical trial in glaucoma (12mths treatment)
- Pipeline targeting other ophthalmic indications
- Platform based technology
- Strong intellectual property position
- Experienced ophthalmic executive team and advisors



# Need for Significant Improvement in Drug Delivery

**Chronic conditions like glaucoma and retinal diseases lead to blindness and severely impact quality of life**



**Eye Drops  
Daily**

- Poor patient compliance
- Cornea is a barrier to drug effectiveness
- Advanced glaucoma patients have multiple drops



**Eye Injections  
Every 4-12  
Weeks**

- Requires frequent injections at physician office
- High burden for both patient and physician
- Risk of endophthalmitis and other complications


**Optimal drug delivery technology will address current issues and improve patient outcomes**

# PREZIA™ Proprietary Platform

Unique and Differentiated Drug Delivery Technology

## Polymeric Prodrug

Poly(urethane-ester) | Poly(triazole-PEG)



Drug  
Drug monomer Biodegradation Architecture

- + PRECISE** Delivers a consistent daily dose of drug tailored to each application
- + CONTROLLED** Delivers treatment 1 week–12+ months, with no burst effect or loss of efficacy
- + VERSATILE** Applicable to any small drug molecule, can deliver multiple agents in a single implant
- + REPEATABLE** Consistent, predictable biodegradation enables repeated implant administration
- + ADAPTABLE** Geometric form can be rod-shaped implant or injectable gel

# US\$4.5B Glaucoma Market Affecting 3 Million in the U.S.

Low patient compliance with drop treatment increases risk of vision loss

## THE PROBLEM:


- Poor adherence to eye drop treatments increases risk of vision loss
- Current implants are single-use only

## THE SOLUTION:

- Sustained drug delivery directed to the target tissues in the eye
- Ability to deliver chronic dosing

## THE MARKET

- U.S. \$4.5 billion
- 3 million treated patients



**!** Two approved sustained release products on market in the U.S. – only approved for single use




# PA5108 Drug Product Description

Uniquely designed through chemistry principles

## PolyActiva's PA5108 Ocular Implant

### Target Product Profile

- ✓ 6-month IOP Lowering Efficacy
- ✓ Constant Daily Delivered Dose
- ✓ Enables Repeat Dose Rx
- ✓ Rapid Biodegradation
- ✓ Administer in Ophthalmologists Office
- ✓ No Implant Movement
- ✓ Minimal to No Endothelial Cell Loss



# Phase 2a Successful Clinical Study – Design and Objective

Key Goal to Establish Safety, Efficacy & Ability to Repeat Dose

## DESCRIPTION

Open-label, comparative, sequential dosing, multi-center interventional study to assess safety, multiple dose IOP-lowering efficacy in adult primary open-angle glaucoma participants

## PRIMARY OBJECTIVES

- Determine the minimum effective dose that achieves an intraocular pressure (IOP) lowering effect  $\geq 20\%$  at 12 weeks
- Assess the safety and tolerability of PA5108 Latanoprost FA SR Ocular Implants at 12 and 27 weeks

## SECONDARY OBJECTIVES

- Determine the minimum effective dose that achieves and IOP lowering effect  $\geq 20\%$  at 26 weeks with minimal AE's
- Demonstrate that an IOP lowering effect  $\geq 20\%$  is maintained until at least Week 42 in the repeat dose cohort.
- Assess the safety and tolerability of PA5108 Latanoprost FA SR Ocular Implant during the course of the study

### Three Treatment Cohorts


Single Dose Cohort  
PA5108 – 80 mcg  
n=10

Single Dose Cohort  
PA5108 – 145 mcg  
n=10

Repeat Dose Cohort  
PA5108 – 80 mcg  
n=17


# Strong Efficacy Demonstrated Over Two Implants

Greater than 7.8mmHg IOP Reduction to 42 Weeks Demonstrates LT Control



# PA5108 Ocular Implant – 8am IOP Cohort 4


Phase 2a: IOP Lowering Efficacy Observed as Early as Day 1 – 80mcg implant



# Ocular Safety Profile Supports Repeat Dosing

Repeat Dose Cohort	SUMMARY	
Adverse Events in Study Eye	Participants	Events
<b>SUMMARY</b>		
Participants with AE's	7/17	
Total Adverse Events		24
<b>DETAIL BY TEAE TYPE</b>		
Redness in the eye	4	6
Light sensitivity	2	2
Foreign Body Sensation	1	2
Corneal oedema	1	2
Punctate keratitis	1	2
Eye pain	1	2
Eye irritation	1	1
Conjunctival oedema	1	1
Anterior Chamber Cells	1	1
Cataract progression	1	1
Corneal Endothelial Cell Loss	1	1
Corneal injury	1	1
Facial pain	1	1
Headache	1	1

## Percentage reduction in corneal endothelial cell densities from baseline



# Phase 2b Ongoing Clinical Study – Design and Objective

Key Goal to Establish Comparable Efficacy to Industry Standard Over 12 Months

## DESCRIPTION

Dose escalation, safety and efficacy in patients with open-angle glaucoma and ocular hypertension  
n = 75

## STUDY OBJECTIVE

- Evaluate the safety, efficacy, chronic dosing potential and 6-month dose duration of 2 Intracameral PA5108 ocular implants
- Determine the dose strength(s) to achieve meaningful ( $\geq 20\%$ ) reduction in mean diurnal IOP

## TYPE OF CONTROL/BLINDING

- Dose-ranging, active-controlled, masked study with a 2:2:1 randomization and compared to latanoprost drops in control arm

### Three Treatment Cohorts

PA5108 Ocular Implant  
80 mcg  
n=30

PA5108 Ocular Implant  
160 mcg  
n=30

Latanoprost Ophthalmic  
Solution 0.005%  
n=15

## Key Study Visits & Criteria

Screening

CECD  $\geq 2000$  cells  
per mm<sup>2</sup>

E1

IOP  $\geq 24$  at 8 am,  
 $\geq 20$  at 10 am & 4 pm

E2 – 1st Implant

IOP  $\geq 24$  at 8 am

W26 – 2nd Implant

W58 – EOS

# Clear Path to Approval and Commercialization

Focused on Ensuring Strong Planning Around Key Approval Factors



## CLINICAL & REGULATORY

### Engagement with FDA

- Proven clinical pathway for Phase 3 and NDA approval
- Will meet with FDA at interim readout of Phase 2b trial
- Phase 3 plan will be completed and in place to move immediately after Phase 2b completion
- 505(b)(2) pathway confirmed



## MANUFACTURING

### GMP manufacturing scale up

- Technical transfer to FDA approved CDMOs complete
- Starting materials and intermediates manufactured to GMP and commercial scale
- Drug Substance and Drug Product scale-up in process at U.S. CMO
- Device manufactured to ISO13485



## REIMBURSEMENT


### Path to market identified

- Pricing and reimbursement pathway determined with DURYSTA as a precedent
- Attractive buy-and-bill model advantageous to physician and practice economics
- Additional primary and secondary market research analysis confirms peak sales **>US\$750M<sup>(1)</sup>**

(1) ClearView Healthcare Independent Research Report

# Current Pipeline

## PREZIA™ Pipeline



# Key Milestones and Future Funding Requirements

## PA5108 – Latanoprost Acid Sustained Release

- Phase 2b Interim Clinical Data Q3 2026
- FDA meeting Q4 2026
- Phase 3 Clinical Trial Initiation Q1 2027

## PA5346 – Latanoprost Acid Sustained Release

- Phase 1b Clinical Data Q4 2026

## PA5691 – Dexamethasone Sustained Release

- Preclinical POC Q2 2026



## FUNDING REQUIREMENTS

- Existing funds covers the ongoing clinical programs
- \$10m for pipeline build (2 new candidates)
- \$100m for phase 3 program – Australian and international investment or potential for IPO late 2026

# Proven Leadership Team

Deep R&D, Operational and Commercial Expertise



**JERRY ST. PETER**

Chief Executive Officer and  
Board Member

**30+ Years Experience**

Xequel Bio, Santen, Eyevance,  
Sun Pharma, Nicox, Merck,  
Inspire, Muro



**WES BRAZELL**

Chief Financial Officer

**30+ Years Experience**

Xequel Bio, Santen, Eyevance,  
TearLab, Alcon, KPMG



**MIKE BRUBAKER, PhD**

Chief Scientific Officer

**30+ Years Experience**

Xequel Bio, Novartis, Alcon,  
Bausch + Lomb, Abbott Labs



**VANESSA WADDELL**

Chief Strategy Officer

**20+ Years Experience**

Starpharma, Inner Maven,  
Prima Biomed, Velacor



# PolyActiva – Transformational Growth & Momentum



Achieved **successful Phase 2a clinical trial results** and currently **enrolling patients in a Phase 2b study** with our lead product, PA5108 for glaucoma patients



**Secured A\$40M Series C financing** in Q2 2025 to catapult growth and value creation

- Brandon Capital
- National Reconstruction Fund Corp



Established business and clinical **operations in the U.S.** while strengthening Technical and R&D **provens in Australia**



**Seasoned ophthalmic executive management team**, with deep R&D, Operational and Commercial expertise, including multiple successful exits and capital raises



**Leveraged PREZIA™ technology**, a proprietary sustained release drug delivery platform, by **advancing back of the eye development programs**



# Proprietary Polymeric Prodrugs

Precise & Controlled Drug  
Delivery to the Eye

October 2025

